Literature DB >> 30173073

Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.

Maria Agallou1, Eleni Pantazi2, Elisavet Tsiftsaki2, Dimitra K Toubanaki1, Catherine Gaitanaki3, Despina Smirlis4, Evdokia Karagouni5.   

Abstract

Leishmania elongation factor 2 (EF-2) has been previously identified as a TH1-stimulatory protein. In this study, we assayed the protective potential of the N-terminal domain of EF-2 (N-LiEF-2, 1-357 aa) that has been predicted to contain several overlapping MHC class I and II-restricted epitopes injected in the form of dendritic cell (DC)-based vaccine. Ex vivo pulsing of DCs with the recombinant N-LiEF-2 domain along with CpG oligodeoxynucleotides (ODNs) resulted in their functional differentiation. BALB/c vaccinated with CpG-triggered DCs pulsed with N-LiEF-2 were found to be the most immune-reactive in terms of induction of DTH responses, increased T cell proliferation and IL-2 production. Moreover, vaccination induced antigen-specific TH1 type immune response as evidenced by increased IFN-γ and TNFα levels followed by a significant increase of nitrite (NO) and reactive oxygen species (ROS) in splenocyte cultures. Vaccinated mice showed a pronounced decrease in parasite load in spleen and liver when challenged with L. infantum, increased expression of Stat1 and Tbx21 mRNA transcripts versus reduced expression of Foxp3 transcripts and were able to produce significantly elevated levels of IL-2, IFN-γ and TNFα but not IL-10 compared to non-vaccinated mice. Both antigen and parasite-specific CD4+ T and CD8+ T cells contributed to the IFN-γ production indicating that both subtypes contribute to the resistance to infection and correlated with robust nitrite generation, critical in controlling Leishmania infection. Together, these findings demonstrated the immunogenic as well as protective potential of the N-terminal domain of Leishmania EF-2 when given with CpG-triggered DCs representing a basis for the development of rationalized vaccine against leishmaniasis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DC-based vaccination; Elongation factor-2; Immune response; Leishmania; T cell epitopes; Visceral leishmaniasis

Mesh:

Substances:

Year:  2018        PMID: 30173073     DOI: 10.1016/j.molimm.2018.08.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Detection of Antigen-specific T cells in Spleens of Vaccinated Mice Applying 3[H]-Thymidine Incorporation Assay and Luminex Multiple Cytokine Analysis Technology.

Authors:  Maria Agallou; Evdokia Karagouni
Journal:  Bio Protoc       Date:  2019-06-05

2.  Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant.

Authors:  Dagmar Hildebrand; Camila Metz-Zumaran; Greta Jaschkowitz; Klaus Heeg
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 3.  Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.

Authors:  Greta Volpedo; Thalia Pacheco-Fernandez; Parna Bhattacharya; Timur Oljuskin; Ranadhir Dey; Sreenivas Gannavaram; Abhay R Satoskar; Hira L Nakhasi
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

4.  An insight into differential protein abundance throughout Leishmania donovani promastigote growth and differentiation.

Authors:  Pedro J Alcolea; Ana Alonso; Francisco García-Tabares; Jaime Larraga; Luis T C Martins; Franciso J Loayza; Silvia Ruiz-García; Vicente Larraga
Journal:  Int Microbiol       Date:  2022-08-05       Impact factor: 3.097

5.  Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Bethina T Steiner; Grasiele S V Tavares; Vívian T Martins; Amanda S Machado; João A Oliveira-da-Silva; Thaís T O Santos; Camila S Freitas; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Maria V Humbert; Myron Christodoulides; Eduardo A F Coelho
Journal:  Vaccines (Basel)       Date:  2020-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.